Addex Financial Statements From 2010 to 2024

ADXN Stock  USD 10.86  0.63  6.16%   
Addex Therapeutics financial statements provide useful quarterly and yearly information to potential Addex Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Addex Therapeutics financial statements helps investors assess Addex Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Addex Therapeutics' valuation are summarized below:
Gross Profit
1.4 M
Market Capitalization
11.6 M
Enterprise Value Revenue
6.2501
Revenue
1.4 M
Earnings Share
(19.96)
We have found one hundred twenty available fundamental signals for Addex Therapeutics, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Addex Therapeutics' prevailing fundamentals against the trend between 2010 and 2024 to make sure the company can sustain itself down the road. As of the 31st of August 2024, Market Cap is likely to grow to about 569.3 M. Also, Enterprise Value is likely to grow to about 541.5 M

Addex Therapeutics Total Revenue

2.67 Million

Check Addex Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Addex Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 159.5 K, Interest Expense of 20.5 K or Total Revenue of 2.7 M, as well as many indicators such as Price To Sales Ratio of 223, Dividend Yield of 0.0 or PTB Ratio of 346. Addex financial statements analysis is a perfect complement when working with Addex Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Addex Therapeutics Correlation against competitors.
To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.

Addex Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets4.4 M4.6 M17.6 M
Slightly volatile
Short and Long Term Debt Total448 K344.3 K486.2 K
Very volatile
Other Current Liabilities1.3 M1.4 MM
Slightly volatile
Total Current LiabilitiesM2.9 M3.4 M
Pretty Stable
Total Stockholder Equity1.1 M1.1 M13.6 M
Slightly volatile
Property Plant And Equipment Net335.3 K352.9 K855 K
Slightly volatile
Current Deferred Revenue412.9 K270.2 K293.5 K
Slightly volatile
Accounts Payable913.8 K984.4 KM
Pretty Stable
Cash3.7 M3.9 M15.4 M
Slightly volatile
Non Current Assets Total386.9 K407.3 K1.4 M
Slightly volatile
Non Currrent Assets Other51.6 K54.3 K565.2 K
Slightly volatile
Cash And Short Term Investments3.7 M3.9 M15.4 M
Slightly volatile
Common Stock Total Equity39.7 M37.8 M20.9 M
Slightly volatile
Common Stock Shares Outstanding78 M74.3 M24.8 M
Slightly volatile
Liabilities And Stockholders Equity4.4 M4.6 M17.6 M
Slightly volatile
Other Current Assets206.2 K217 K58.6 M
Slightly volatile
Other Stockholder Equity288.6 M329.9 M268.1 M
Slightly volatile
Total Liabilities4.5 M3.5 M4.1 M
Very volatile
Property Plant And Equipment Gross2.4 M4.7 M1.8 M
Pretty Stable
Total Current AssetsM4.2 M16.2 M
Slightly volatile
Short Term Debt193.4 K274 K133.1 K
Slightly volatile
Common Stock1.8 M1.8 M15 M
Pretty Stable
Non Current Liabilities Total761.6 K603.1 K703.7 K
Slightly volatile
Net Receivables271.7 K151.3 K420.8 K
Slightly volatile
Other Assets66 K48.9 K152.6 K
Slightly volatile
Capital Surpluse297.8 M329.3 M277.1 M
Slightly volatile
Property Plant Equipment275.1 K458.5 K210.9 K
Slightly volatile
Net Invested Capital1.1 M1.1 M7.6 M
Pretty Stable
Net Working Capital1.3 M1.3 MM
Pretty Stable
Capital Stock1.8 M1.8 M25.1 M
Slightly volatile

Addex Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization159.5 K167.9 K666.4 K
Slightly volatile
Total Revenue2.7 M1.6 MM
Pretty Stable
Other Operating Expenses16.8 M11.9 M14.8 M
Pretty Stable
Research Development2.6 M2.7 M5.5 M
Pretty Stable
Total Operating Expenses15.5 M11.9 M12.8 M
Very volatile
Selling General Administrative4.7 M7.2 M5.5 M
Pretty Stable
Interest Income65.8 K64 K101.8 K
Slightly volatile
Reconciled Depreciation268.3 K306 K138.8 K
Slightly volatile

Addex Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation1.2 M1.8 M1.1 M
Slightly volatile
Begin Period Cash Flow6.6 MM18.3 M
Slightly volatile
Depreciation290.7 K306 K691.8 K
Slightly volatile
End Period Cash Flow3.7 M3.9 M15.4 M
Slightly volatile
Issuance Of Capital Stock2.2 M2.4 M25.7 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2232341.5 K
Very volatile
PTB Ratio346330172
Slightly volatile
Days Sales Outstanding32.5234.23091.3 K
Slightly volatile
Book Value Per Share0.01460.01548.1851
Slightly volatile
Average Payables1.4 M1.4 M944 K
Slightly volatile
Stock Based Compensation To Revenue1.061.11252.8754
Slightly volatile
Capex To Depreciation0.02120.02240.3745
Very volatile
PB Ratio346330172
Slightly volatile
Sales General And Administrative To Revenue4.244.466924.6508
Slightly volatile
Research And Ddevelopement To Revenue1.621.70410.9267
Slightly volatile
Capex To Revenue0.0040.00420.368
Slightly volatile
Cash Per Share0.04940.0528.1737
Slightly volatile
Intangibles To Total Assets0.00230.0030.0034
Very volatile
Net Debt To EBITDA0.340.35532.8777
Very volatile
Current Ratio1.391.46364.483
Pretty Stable
Tangible Book Value Per Share0.01460.01548.1707
Slightly volatile
Receivables Turnover8.2410.66298.8067
Slightly volatile
Graham Number0.210.22229.8777
Slightly volatile
Shareholders Equity Per Share0.01460.01548.1851
Slightly volatile
Debt To Equity0.320.30060.0576
Slightly volatile
Capex Per Share1.0E-41.0E-40.0644
Slightly volatile
Average Receivables359.7 K530.6 K325.2 K
Very volatile
Revenue Per Share0.02060.02170.8641
Slightly volatile
Interest Debt Per Share0.00470.00490.0431
Slightly volatile
Debt To Assets0.07790.07420.0205
Slightly volatile
Price Book Value Ratio346330172
Slightly volatile
Ebt Per Ebit0.721.02671.0014
Pretty Stable
Company Equity Multiplier4.264.05242.2777
Pretty Stable
Long Term Debt To Capitalization0.06080.05790.0156
Slightly volatile
Total Debt To Capitalization0.240.23110.047
Slightly volatile
Debt Equity Ratio0.320.30060.0576
Slightly volatile
Quick Ratio1.391.463622.1843
Slightly volatile
Cash Ratio1.271.3364.2466
Pretty Stable
Days Of Sales Outstanding32.5234.23091.3 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.141.00091.0133
Slightly volatile
Price To Book Ratio346330172
Slightly volatile
Fixed Asset Turnover4.344.570159.8939
Very volatile
Debt Ratio0.07790.07420.0205
Slightly volatile
Price Sales Ratio2232341.5 K
Very volatile
Asset Turnover0.360.34750.1208
Slightly volatile
Price Fair Value346330172
Slightly volatile

Addex Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap569.3 M378 M888.1 M
Slightly volatile

Addex Fundamental Market Drivers

Cash And Short Term Investments3.9 M

Addex Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Addex Therapeutics Financial Statements

Addex Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Addex Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue270.2 K412.9 K
Total Revenue1.6 M2.7 M
Cost Of Revenue6.9 M5.6 M
Stock Based Compensation To Revenue 1.11  1.06 
Sales General And Administrative To Revenue 4.47  4.24 
Research And Ddevelopement To Revenue 1.70  1.62 
Revenue Per Share 0.02  0.02 
Ebit Per Revenue(6.37)(6.69)

Pair Trading with Addex Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Addex Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Addex Therapeutics will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Addex Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Addex Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Addex Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Addex Therapeutics to buy it.
The correlation of Addex Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Addex Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Addex Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Addex Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Information and Resources on Investing in Addex Stock

When determining whether Addex Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Addex Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Addex Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Addex Therapeutics Stock:
Check out the analysis of Addex Therapeutics Correlation against competitors.
To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.
You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Addex Therapeutics. If investors know Addex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Addex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(19.96)
Revenue Per Share
2.04
Quarterly Revenue Growth
(0.53)
Return On Assets
(1.26)
Return On Equity
(8.10)
The market value of Addex Therapeutics is measured differently than its book value, which is the value of Addex that is recorded on the company's balance sheet. Investors also form their own opinion of Addex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Addex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Addex Therapeutics' market value can be influenced by many factors that don't directly affect Addex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Addex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Addex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Addex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.